Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR440234 in R/R AML, B-ALL, or HR-MDS
NCT03594955Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of sar440234 in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndrome (MDS), sponsored by Sanofi. Started Oct 2018; status: terminated.
02
Drugs
sar440234
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03594955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594955.